The DREAM-SEQ trial is a landmark study that demonstrated superiority of frontline ICI combination versus combination BRAFMEK inhibition as frontline therapy for patients with BRAF V600E/K -mutant, advanced melanoma
Erabi H, Okada G, Shibasaki C, Setoyama D, Kang D, Takamura M, et al
Seven additional Phase 3 trials from the TRIUMPH program are expected to report results throughout 2026, including trials in type 2 diabetes, obstructive sleep apnea, and general obesity without specific comorbidities
Such regimens have been reported to result in cumulative doses reaching 40100 times higher than physiological testosterone levels
For those truly once-in-a-lifetime events, like a dream wedding, planning a full month ahead is ideal
Ne pas dpasser la dose journalire indique